Literature DB >> 21840315

Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein.

Robert D Gaffin1, James R Peña, Marco S L Alves, Fernando A L Dias, Shamim A K Chowdhury, Lynley S Heinrich, Paul H Goldspink, Evangelia G Kranias, David F Wieczorek, Beata M Wolska.   

Abstract

We have recently shown that a temporary increase in sarcoplasmic reticulum (SR) cycling via adenovirus-mediated overexpression of sarcoplasmic reticulum ATPase (SERCA2) transiently improves relaxation and delays hypertrophic remodeling in a familial hypertrophic cardiomyopathy (FHC) caused by a mutation in the thin filament protein, tropomyosin (i.e., α-TmE180G or Tm180). In this study, we sought to permanently alter calcium fluxes via phospholamban (PLN) gene deletion in Tm180 mice in order to sustain long-term improvements in cardiac function and adverse cardiac remodeling/hypertrophy. While similar work has been done in FHCs resulting from mutations in thick myofilament proteins, no one has studied these effects in an FHC resulting from a thin filament protein mutation. Tm180 transgenic (TG) mice were crossbred with PLN knockout (KO) mice and four groups were studied in parallel: 1) non-TG (NTG), 2) Tm180, 3) PLNKO/NTG and 4) PLNKO/Tm180. Tm180 mice exhibit increased heart weight/body weight and hypertrophic gene markers compared to NTG mice, but levels in PLNKO/Tm180 mice were similar to NTG. Tm180 mice also displayed altered function as assessed via in situ pressure-volume analysis and echocardiography at 3-6 months and one year; however, altered function in Tm180 mice was rescued back to NTG levels in PLNKO/Tm180 mice. Collagen deposition, as assessed by Picrosirius Red staining, was increased in Tm180 mice but was similar in NTG and in PLNKO/Tm180 mice. Extracellular signal-regulated kinase (ERK1/2) phosphorylation increased in Tm180 mice while levels in PLNKO/Tm180 mice were similar to NTGs. The present study shows that by modulating SR calcium cycling, we were able to rescue many of the deleterious aspects of FHC caused by a mutation in the thin filament protein, Tm.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840315      PMCID: PMC3221410          DOI: 10.1016/j.yjmcc.2011.07.026

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  55 in total

1.  Phospholamban ablation and compensatory responses in the mammalian heart.

Authors:  G Chu; D G Ferguson; I Edes; E Kiss; Y Sato; E G Kranias
Journal:  Ann N Y Acad Sci       Date:  1998-09-16       Impact factor: 5.691

2.  Re-evaluating sarcoplasmic reticulum function in heart failure.

Authors:  U Delling; M A Sussman; J D Molkentin
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

3.  Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy.

Authors:  S Minamisawa; M Hoshijima; G Chu; C A Ward; K Frank; Y Gu; M E Martone; Y Wang; J Ross; E G Kranias; W R Giles; K R Chien
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

4.  Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy.

Authors:  James R Peña; Ariani C Szkudlarek; Chad M Warren; Lynley S Heinrich; Robert D Gaffin; Ganapathy Jagatheesan; Federica del Monte; Roger J Hajjar; Paul H Goldspink; R John Solaro; David F Wieczorek; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2010-09-18       Impact factor: 5.000

5.  The enhanced contractility in phospholamban deficient mouse hearts is not associated with alterations in (Ca2+)-sensitivity or myosin ATPase-activity of the contractile proteins.

Authors:  R H Schwinger; K Brixius; P Savvidou-Zaroti; B Bölck; C Zobel; K Frank; E G Kranias; S Hoischen; E Erdmann
Journal:  Basic Res Cardiol       Date:  2000-02       Impact factor: 17.165

6.  Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice.

Authors:  Tong Zhang; Tao Guo; Shikha Mishra; Nancy D Dalton; Evangelia G Kranias; Kirk L Peterson; Donald M Bers; Joan Heller Brown
Journal:  Circ Res       Date:  2009-12-03       Impact factor: 17.367

Review 7.  Molecular targets and regulators of cardiac hypertrophy.

Authors:  Agrawal Rohini; Neeraj Agrawal; Chintan N Koyani; Randhir Singh
Journal:  Pharmacol Res       Date:  2009-12-05       Impact factor: 7.658

Review 8.  Hypertrophic cardiomyopathy as a cause of sudden death.

Authors:  Hubert Seggewiss; Christoph Blank; Barbara Pfeiffer; Angelos Rigopoulos
Journal:  Herz       Date:  2009-06       Impact factor: 1.443

Review 9.  Familial hypertrophic cardiomyopathy: basic concepts and future molecular diagnostics.

Authors:  Jessica E Rodríguez; Christopher R McCudden; Monte S Willis
Journal:  Clin Biochem       Date:  2009-02-09       Impact factor: 3.281

Review 10.  Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes.

Authors:  Marco L Alves; Robert D Gaffin; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2010-01-15       Impact factor: 5.000

View more
  21 in total

1.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

Review 2.  Therapeutic Strategies Targeting Inherited Cardiomyopathies.

Authors:  Kenneth Varian; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2017-08

3.  Microarray analysis of active cardiac remodeling genes in a familial hypertrophic cardiomyopathy mouse model rescued by a phospholamban knockout.

Authors:  Sudarsan Rajan; James R Pena; Anil G Jegga; Bruce J Aronow; Beata M Wolska; David F Wieczorek
Journal:  Physiol Genomics       Date:  2013-06-25       Impact factor: 3.107

Review 4.  Novel Therapies for Prevention and Early Treatment of Cardiomyopathies.

Authors:  Giuliana G Repetti; Christopher N Toepfer; Jonathan G Seidman; Christine E Seidman
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

5.  Tropomyosin dephosphorylation results in compensated cardiac hypertrophy.

Authors:  Emily M Schulz; Richard N Correll; Hajer N Sheikh; Marco S Lofrano-Alves; Patti L Engel; Gilbert Newman; Jo El J Schultz; Jeffery D Molkentin; Beata M Wolska; R John Solaro; David F Wieczorek
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

Review 6.  Tropomyosin de-phosphorylation in the heart: what are the consequences?

Authors:  Emily M Schulz; David F Wieczorek
Journal:  J Muscle Res Cell Motil       Date:  2013-06-22       Impact factor: 2.698

7.  Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.

Authors:  Marco L Alves; Fernando A L Dias; Robert D Gaffin; Jillian N Simon; Eric M Montminy; Brandon J Biesiadecki; Aaron C Hinken; Chad M Warren; Megan S Utter; Robert T Davis; Sadayappan Sakthivel; Jeffrey Robbins; David F Wieczorek; R John Solaro; Beata M Wolska
Journal:  Circ Cardiovasc Genet       Date:  2014-02-28

8.  Decreasing tropomyosin phosphorylation rescues tropomyosin-induced familial hypertrophic cardiomyopathy.

Authors:  Emily M Schulz; Tanganyika Wilder; Shamim A K Chowdhury; Hajer N Sheikh; Beata M Wolska; R John Solaro; David F Wieczorek
Journal:  J Biol Chem       Date:  2013-08-19       Impact factor: 5.157

9.  Conserved Asp-137 is important for both structure and regulatory functions of cardiac α-tropomyosin (α-TM) in a novel transgenic mouse model expressing α-TM-D137L.

Authors:  Sumeyye Yar; Shamim A K Chowdhury; Robert T Davis; Minae Kobayashi; Michelle M Monasky; Sudarsan Rajan; Beata M Wolska; Vadim Gaponenko; Tomoyoshi Kobayashi; David F Wieczorek; R John Solaro
Journal:  J Biol Chem       Date:  2013-04-22       Impact factor: 5.157

10.  In Vivo Analysis of Troponin C Knock-In (A8V) Mice: Evidence that TNNC1 Is a Hypertrophic Cardiomyopathy Susceptibility Gene.

Authors:  Adriano S Martins; Michelle S Parvatiyar; Han-Zhong Feng; J Martijn Bos; David Gonzalez-Martinez; Milica Vukmirovic; Rajdeep S Turna; Marcos A Sanchez-Gonzalez; Crystal-Dawn Badger; Diego A R Zorio; Rakesh K Singh; Yingcai Wang; J-P Jin; Michael J Ackerman; Jose R Pinto
Journal:  Circ Cardiovasc Genet       Date:  2015-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.